{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:16:16Z","timestamp":1774340176775,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015498","name":"Innov\u00e1ci\u00f3s \u00e9s Technol\u00f3giai Miniszt\u00e9rium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bmcl.2024.129970","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T01:12:18Z","timestamp":1726794738000},"page":"129970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Harnessing dual-mode RIPK1 ligands for cross-species anti-necroptosis inhibitor compounds"],"prefix":"10.1016","volume":"113","author":[{"given":"J\u00f3zsef","family":"Levente Petr\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Bana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolett","family":"Linke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Eszter Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"Katalin Szalai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ildik\u00f3","family":"K\u00e1lomista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Csaba","family":"G\u00e1bor Vass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Horny\u00e1nszky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"\u00c9les","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2024.129970_b0005","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41573-020-0071-y","article-title":"Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target","volume":"19","author":"Mifflin","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2024.129970_b0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41583-018-0093-1","article-title":"Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases","volume":"20","author":"Yuan","year":"2019","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmcl.2024.129970_b0015","doi-asserted-by":"crossref","first-page":"1159743","DOI":"10.3389\/fimmu.2023.1159743","article-title":"Targeting RIPK1 kinase for modulating inflammation in human diseases","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2024.129970_b0020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.semcdb.2020.06.014","article-title":"RIPk protein kinase family: atypical lives of typical kinases","volume":"109","author":"Cuny","year":"2021","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.bmcl.2024.129970_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107979","article-title":"Novel insights into RIPK1 as a promising target for future Alzheimer\u2019s disease treatment","volume":"231","author":"Li","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2024.129970_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107717","article-title":"A decade of cell death studies: Breathing new life into necroptosis","volume":"220","author":"Khan","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bmcl.2024.129970_b0035","first-page":"771","article-title":"RIP1\/RIP3-regulated necroptosis as a target for multifaceted disease therapy (Review)","volume":"44","author":"Liu","year":"2019","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.bmcl.2024.129970_b0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.tips.2020.01.002","article-title":"Inhibitors targeting RIPK1\/RIPK3: old and new drugs","volume":"41","author":"Martens","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.bmcl.2024.129970_b0045","article-title":"Advances in RIPK1 kinase inhibitors","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmcl.2024.129970_b0050","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1021\/acs.jmedchem.6b01751","article-title":"Discovery of a first-in-class receptor interacting protein 1 (RIP1) kinase specific clinical candidate (GSK2982772) for the treatment of inflammatory diseases","volume":"60","author":"Harris","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129970_b0055","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1021\/acs.jmedchem.5b01898","article-title":"DNA-encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interactingprotein 1 kinase inhibitors","volume":"59","author":"Harris","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129970_b0060","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1021\/acs.jmedchem.7b01647","article-title":"Discovery of 7-Oxo-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine derivatives as potent, orally available, and brain-penetrating receptor interacting protein 1 (RIP1) kinase inhibitors: analysis of structure\u2212kinetic relationships","volume":"61","author":"Yoshikawa","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129970_b0065","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acsmedchemlett.9b00108","article-title":"Identification of a RIP1 kinase inhibitor clinical candidate (GSK3145095) for the treatment of pancreatic cancer","volume":"10","author":"Harris","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129970_b0070","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bmcl.2019.04.014","article-title":"Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group","volume":"29","author":"Hamilton","year":"2019","journal-title":"Bioorganic Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129970_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113484","article-title":"Structure-based bioisosterism design of thio-benzoxazepinones as novel necroptosis inhibitors","volume":"220","author":"Xia","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2024.129970_b0080","article-title":"Potent and Selective RIPK1 Inhibitors Targeting Dual-Pockets for the Treatment of Systemic Inflammatory Response Syndrome and Sepsis","volume":"61","author":"Yang","year":"2022","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmcl.2024.129970_b0085","article-title":"Discovery of novel biaryl benzoxazepinones as dual-mode receptor-interacting protein kinase-1 (RIPK1) inhibitors","volume":"100","author":"Xin","year":"2024","journal-title":"Bioorganic Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129970_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129643","article-title":"Design synthesis and biological evaluation of novel cyclic malonamide derivatives as selective RIPK1 inhibitors","volume":"100","author":"Petr\u00f3","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2024.129970_b0095","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41418-021-00742-x","article-title":"A toolbox for imaging RIPK1, RIPK3, and MLKL in mouse and human cells","volume":"28","author":"Samson","year":"2021","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.bmcl.2024.129970_b0100","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1021\/acs.orglett.9b02175","article-title":"Highly carbon-selective monofluoromethylation of \u03b2-ketoesters with fluoromethyl iodide","volume":"21","author":"Ding","year":"2019","journal-title":"Org Lett"},{"key":"10.1016\/j.bmcl.2024.129970_b0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41418-019-0347-0","article-title":"RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases","volume":"27","author":"Patel","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bmcl.2024.129970_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127417","article-title":"New V1a receptor antagonist. Part 2. Identification and optimization of triazolobenzazepines","volume":"30","author":"Boz\u00f3","year":"2020","journal-title":"Bioorganic Med Chem Lett"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2400372X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2400372X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:17:46Z","timestamp":1729099066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2400372X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":22,"alternative-id":["S0960894X2400372X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129970","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Harnessing dual-mode RIPK1 ligands for cross-species anti-necroptosis inhibitor compounds","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2024.129970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129970"}}